196 related articles for article (PubMed ID: 26651595)
1. UK guidance opens new therapeutic avenues for patients with moderate-severe ulcerative colitis.
Orchard T
Expert Rev Gastroenterol Hepatol; 2016; 10(3):281-2. PubMed ID: 26651595
[No Abstract] [Full Text] [Related]
2. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
3. Golimumab for moderate to severe ulcerative colitis.
Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
5. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
6. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
[TBL] [Abstract][Full Text] [Related]
7. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
9. Overview of biological therapy in ulcerative colitis: current and future directions.
Furfaro F; Bezzio C; Ardizzone S; Massari A; de Franchis R; Maconi G
J Gastrointestin Liver Dis; 2015 Jun; 24(2):203-13. PubMed ID: 26114181
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
12. Biological therapy for ulcerative colitis: an update.
Seo GS; Chae SC
World J Gastroenterol; 2014 Oct; 20(37):13234-8. PubMed ID: 25309060
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
14. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
Dumitrescu G; Dahan K; Treton X; Corcos O; Bouhnik Y; Stefanescu C
J Gastrointestin Liver Dis; 2015 Jun; 24(2):249-51. PubMed ID: 26114187
[TBL] [Abstract][Full Text] [Related]
15. Efficient Early Drug Development for Ulcerative Colitis.
Khanna R; Jairath V; Vande Casteele N; Mosli MH; Zou G; Parker CE; Levesque BG; Sandborn WJ; D'Haens G; Feagan BG
Gastroenterology; 2016 May; 150(5):1056-1060. PubMed ID: 27018491
[No Abstract] [Full Text] [Related]
16. [Anti-TNF-alpha therapy in ulcerative colitis].
Lakatos PL; Lakatos L
Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
[TBL] [Abstract][Full Text] [Related]
17. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S
Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212
[TBL] [Abstract][Full Text] [Related]
18. Ulcerative colitis: prevention of relapse.
Naganuma M; Sakuraba A; Hibi T
Expert Rev Gastroenterol Hepatol; 2013 May; 7(4):341-51. PubMed ID: 23639092
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
20. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
